Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 15/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25345505 | 0.85 | HTR2A (0.55) | HTR2AHTR6SCN9A | |
| SCHEMBL28638911 | 0.80 | HTR2A (0.49) | HTR2AHTR6SCN9A | |
| SCHEMBL1858950 | 0.79 | KDM4E (0.41) | BCHEACHECREBBP | |
| SCHEMBL4776240 | 0.79 | HTR2A (0.48) | HTR2AHTR6SCN9A | |
| SCHEMBL28979708 | 0.78 | CDC25A (0.46) | OXER1BCHEACHE | |
| SCHEMBL28979721 | 0.78 | CDC25A (0.46) | OXER1BCHEACHE | |
| SCHEMBL28979704 | 0.78 | CDC25A (0.46) | OXER1BCHEACHE | |
| SCHEMBL28979727 | 0.78 | CDC25A (0.46) | OXER1BCHEACHE | |
| SCHEMBL28054185 | 0.78 | KDM4E (0.40) | BCHEACHECREBBP | |
| SCHEMBL27174180 | 0.77 | HTR2A (0.59) | HTR2AHTR6SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592350-B2 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2009-09-22 | — | — | US | disclosed |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | disclosed |
| EP-1490361-B1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORP (FI) | 2007-10-03 | — | — | EP | disclosed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | disclosed |
| EP-1490361-A1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORPORATION (FI) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082866-A1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORPORATION (FI) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | HTR2A 229/4885HTR6 293/4885SCN9A 462/4885 |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | HTR2A 229/4885HTR6 293/4885SCN9A 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.